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Persistent viral infections are the result of a series of connected events that culminate in diminished immunity
and the inability to eliminate infection. By building our understanding of how distinct components of the
immune system function both individually and collectively in productive versus abortive responses, new
potential therapeutic targets can be developed to overcome immune dysfunction and thus fight persistent
infections. Using lymphocytic choriomeningitis virus (LCMV) as a model of a persistent virus infection and
drawing parallels to persistent human viral infections such as human immunodeficiency virus (HIV) and
hepatitis C virus (HCV), we describe the cellular relationships and interactions that determine the outcome
of initial infection and highlight immune targets for therapeutic intervention to prevent or treat persistent
infections. Ultimately, these findings will further our understanding of the immunologic basis of persistent
viral infection and likely lead to strategies to treat human viral infections.Introduction
Persistent viral infections such as HIV, hepatitis B virus (HBV),
and hepatitis C virus (HCV) cause a tremendous disease burden
with more than 500 million people infected worldwide. The
establishment of a persistent infection is the result of a myriad
of factors mediated by both the virus (e.g., viral mutation, escape
from immune recognition, viral tropism) and host (e.g., suppres-
sive factors, apoptosis, excessive immune activation). While
viruses have evolved mechanisms to modulate and escape
host immunity, the interactions and interplay of innate and adap-
tive immune responses are critical aspects that determine viral
persistence. The immune system is composed of a network of
cell types that reciprocally regulate each other to determine
the scope and direction of the immune response (Figure 1).
Understandably, however, laboratories most often focus their
research on one immune population to facilitate experimenta-
tion. Yet, the functions and interactions between multiple
immune cell populations contribute to the outcome of the viral
infection. Understanding these interactions will foster both a
better understanding of viral infection and illuminate potential
points for therapeutic intervention.
Viruses employ a variety of methods to establish persistence;
however, two main strategies have been noted. Some viruses,
such as those of the herpesviridae family, generate a latent/reac-
tivating infection in which the virus lies dormant within host cells
to escape immune surveillance. Infection with these viruses are
characterized by long periods with little or no viral activity inter-
spersed with periods of reactivation when viral activity ree-
merges but is quickly controlled by the immune system.
Comparatively, viral infections such as HIV, HBV, HCV, and lym-
phocytic choriomeningitis virus (LCMV) have sustained viremia.
In addition to virus-encoded evasion strategies, from an immu-
nologic standpoint, persistence of these viruses is maintained652 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.primarily by immune dysregulation and suppression (Wherry,
2011; Wilson and Brooks, 2010), and thus, interfering with
immune cell activity is necessary for orchestrating antiviral
responses and clearing viral infection. Such chronic infections
are characterized by high levels of viral replication, chronic
immune activation, lymphoid disorganization, heightened/
sustained expression of negative immune regulatory factors,
and dysfunctional/attenuated T and B cell responses (Wherry,
2011) (Table 1). While viruses in both categories impair immunity,
latent viral infections are generally well controlled. Consequently,
this review will focus on the latter strategy of chronic viral infec-
tion because of the especially heavy impact on immune function
and the high morbidity and mortality of these diseases. We will
discuss several important host immune players (Figure 1) as
highlighted by the study of LCMV to showcase the importance
of understanding the network of immunological events that
occur during persistent infection and relate these findings to
chronic viral infections in humans.
LCMV: A Prototypic Model of Immunity to Viral Infection
LCMV infection of its natural host,Mus musculus, has served as
the prototypic system to explore host-virus interactions and
identify key determinants of viral clearance or persistence. The
LCMV system has led to many seminal virological and immuno-
logical discoveries that have subsequently been applied to
human immune responses and infections. The great advantages
of LCMV are the simplicity of its genome (four genes) and that it is
nonlytic, allowing study of structural, cellular, and biochemical
changes of the host’s immune response without the complica-
tion of direct viral cytopathicity. A unique attribute of the LCMV
system is the ability to directly compare immune responses to
two genetically similar viral variants, Armstrong53b (ARM) and
Clone 13 (Cl-13), that respectively establish acute and persistent
Figure 1. Relationship of Immune Cell
Populations during Viral Infection
Simplified schematic of the relationships between
important cell populations during persistent viral
infection. During viral infection, a number of
cellular interactions occur that are important in
determining the scope and direction of the
immune response. Plasmacytoid dendritic cells
(pDC) detect viral antigen and release type I IFN,
which is essential in activation myeloid dendritic
cells (mDC), macrophages (mV), CD4 T cells
(CD4), and CD8 T cells (CD8). Antigen-presenting
cells, as well as pDCs, are necessary for CD4 and
CD8 T cell activation and the interactions of these
cell types is controlled by chemokines secreted by
fibroblastic reticular cells (FRCs). FRCs addition-
ally secrete T cell survival factors. Follicular den-
dritic cells (FDCs) serve a similar role for B cells
and coordinate B cell migration and B and CD4
T cell interactions. CD4 T cell help is necessary for
a number of immune cell types, including CD8
T cells, mDCs, B cells (B), and FRCs. Conversely,
natural killer cells (NK) may regulate the size of key
immune populations.
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(Ahmed et al., 1984). ARM induces a robust T cell response
that clears the infection by 10 days postinfection. In contrast,
Cl-13 replicates to much higher titers, inducing multiple host-
based suppressive pathways, thereby generating a systemic
persistent infection that remains viremic and replicates in the
majority of tissues for 60–90 days, at which point the virus re-
mains in the CNS for extended periods of time and the kidney
for the life of the host (Ahmed et al., 1984; Fahey and Brooks,
2010a; Lauterbach et al., 2007). Although human viruses are
distinct from LCMV, the immune events that occur during persis-
tent LCMV are similar to what is observed in HIV (Wilson and
Brooks, 2010). Hence, it is becoming clear that prolonged virus
infection and sustained viremia institute distinct immunologic
programs that are conserved across species (Youngblood
et al., 2012).
Initiating Adaptive Immunity: A Central Role for DCs
DCs are a heterogeneous population of sentinel cells that
sample antigens that are subsequently presented on the DC
surface to naive T cells to initiate adaptive immune responses.
These antigen-presenting cells (APC) are essential to initiate
the immune response as well as determine its direction, quality,
and quantity (Pulendran, 2004). Three principal groups of DCs
are found within the spleens and lymph nodes of mice: (1)
myeloid CD11c+CD11b+CD8a DCs (CD8a DCs), (2) myeloid
CD11c+CD11b+CD8a+ DCs (CD8a+ DCs), and (3) plasmacytoid
DCs (pDCs; CD11cmidB220+Siglec-H+). pDCs are the rarest
DC type and, upon viral infection, secrete high levels of type I in-
terferons (IFN-I) after recognition of viral nucleic acids by toll-like
receptors (TLR) 7 or 9 (Gilliet et al., 2008). IFN-I are critical for the
initial control of virus infection and abrogation of TLR-signaling in
pDCs diminishes IFN-I production and potentially the ability to
control persistent Cl-13 infection (Blasius et al., 2012; Cer-
vantes-Barragan et al., 2012), although the exact contribution
of IFN-I by pDC in viral clearance remains controversial (Wang
et al., 2012). Because IFN-I is important in fighting viral infection,
disruption of pDC function is common in persistence. pDCs aretargets of Cl-13 (Bergthaler et al., 2010; Macal et al., 2012) and
HIV (Fitzgerald-Bocarsly and Jacobs, 2010). HIV interferes with
pDC function by delaying the production of IFNa (Turk et al.,
2013), and pDC capacity to produce IFNa is decreased during
chronic HIV and HBV infection (Ladell et al., 2013; Mendoza
et al., 2013). The decrease in IFNa may negatively impact
DC maturation and function and T cell activation (Cervantes-
Barragan et al., 2012; Frenz et al., 2010; Le Bon et al., 2003).
IFN-I is important for activation and/or expansion of naive CD4
and CD8 T cells (Havenar-Daughton et al., 2006; Welsh et al.,
2012) and pDCs are integral to this process (Cervantes-Barragan
et al., 2012).
CD8a and CD8a+ DCs are classical DC subsets that activate
naive T cells by presenting antigen on major histocompatibility
complex (MHC) I and MHC II, in conjunction with costimulatory
ligands. CD8a+ DCs are the most efficient for crosspresentation,
whereby extracellular antigen is taken up and presented onMHC
I to CD8 T cells (Iyer et al., 2012). Similar to pDCs, CD8a DCs
are infected at high rates during Cl-13 infection (Ng and Old-
stone, 2012; Sevilla et al., 2000) and, productive DC infection
is likely necessary for establishing Cl-13 persistence (Popkin
et al., 2011). Mice with DCs that are unable to produce infectious
virus do not generate a persistent Cl-13 infection and clear the
virus in a similar manner to LCMV-ARM infection (Sullivan
et al., 2011); comparably, ARM only minimally infects DCs.
Although HIV uses different mechanisms, HIV also utilizes DCs
to establish and maintain infection (Wu and KewalRamani,
2006). DCs disseminate HIV by either direct infection or by trans-
porting virus via the DC-specific lectin DC-SIGN to HIV-specific
T cells in lymph nodes (Wu and KewalRamani, 2006), a phenom-
enon that has also been observed in HCV infection (Frenz et al.,
2010). Beyond viral dissemination, persistent viral infection may
also interfere with DC function. Myeloid DCs isolated from HIV
and HBV patients have reduced capacity to stimulate T cells
(Fitzgerald-Bocarsly and Jacobs, 2010; Ladell et al., 2013).
Cl-13 infection decreases cell-surface expression of MHC I,
MHC II, and T cell costimulatory molecules, CD80, CD86, and
CD40 in both CD8a and CD8a+ DCs, which may interfere withCell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc. 653
Table 1. Cellular Behaviors Observed during Persistent Viral
Infection
Plasmacytoid DCs Increased IFN-I at onset of infection
Impaired IFNa production in chronic phase of
infection
Myeloid DCs Impaired DC function (YMHV, YT cell activation)
Expression of suppressive factors (IL-10, IDO,
PD-L1)
CD4 cells Progressive loss of function associated with
expression of inhibitory receptors and inhibition
by IL-10
Decreased IL-2 production likely decreases CD8
T cell response
Increased IL-21 production maintains function
of antiviral CD8 T cells and promotes B cell
responses
CD8 T cells Progressive loss of function associated with
expression of inhibitory receptors and inhibition
by IL-10
B cells Elevated nonspecific antibody production
B cell deletion and intrinsic dysfunction
Lymphoid stromal
cells
Disorganization and/or loss of FRCs decreases
T cell survival and alters normal lymphocyte
trafficking
Increased PD-L1 on FRCs prevents
immunopathology but augments T cell exhaustion
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(Sevilla et al., 2004). The decrease in DC function may be further
compounded by inhibition of DC differentiation and maturation
(Sevilla et al., 2004). Future studies are important to identify
the fundamental outcomes of DC infection during persistent
infection and how they lead to distinct aspects of immune
dysfunction.
Lymphoid Environment and Lymphocyte Activation
To initiate immune responses, APCs travel to secondary
lymphoid organs (SLOs) such as lymph nodes, spleen, Peyer’s
patches, and tonsils. Within SLOs, naive T cells interact with
APCs, encounter soluble signals and antigens, and undergo
activation. These interactions are spatially and temporally coor-
dinated by fibroblastic reticular cells (FRCs), a specialized non-
hematopoietic stromal foundwithin T cell zones of SLOs (Mueller
and Germain, 2009). FRCs are the foundation for the reticular
network, which compartmentalizes T cell zones; transports anti-
gen and small proteins; and provides a surface for the adhesion,
migration, and interaction of the innate and adaptive immune
cells (Mueller and Germain, 2009). FRCs induce migration of
DCs and naive T cells by expressing chemokines CCL19 and
CCL21 (Mueller and Germain, 2009), which draw these cells to
T cell zones where DCs identify antigen-specific T cells (Junt
et al., 2008). During acute ARM infection, FRCs transiently down-
regulate CCL21 in an IFN-g-dependent manner after infection,
thus slowing movement into the T cell zone (Mueller et al.,
2007a). Follicular DCs, a stromal cell population in B cells zones,
serve a similar structural/conduit role in B cell zones, in addition
to their other critical role in antigen capture and stimulation of the
B cell reaction. Follicular DCs downregulate CXCL13, thus abro-
gatingmovement into B cell zones (Mueller et al., 2007a). Though654 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.transient downregulation of chemokines is hypothesized to
reduce competition for resources, control the size of the immune
response, and promote egress of anti-viral T cells, this downre-
gulation also affects the generation of T cell responses against
cochallenges several days after the initial challenge (Mueller
et al., 2007a). This likely occurs during persistent infection (Tei-
jaro et al., 2013) and would hinder the activation of new anti-viral
T cells needed to counteract T cell exhaustion, death, viral
escape, and secondary infections (Vezys et al., 2006).
In conjunction with coordination and structure, FRCs provide
important regulatory signals that control lymphocyte survival,
including IL-7, a crucial survival signal for naive T cells (Siegert
and Luther, 2012; Zeng et al., 2012a). Reciprocally, T cells
secrete lymphotoxin-b (LT-b), a survival factor for FRCs (Zeng
et al., 2012b), and are the main source of IFN-g, which induces
FRC expression of MHC II molecule and other molecules that
stimulate or suppress T cell responses (Mueller et al., 2007b;
Ng et al., 2012). Because the interaction of lymphocytes and
stromal cells is important in homeostasis and immune activation,
interrupting the integrity of the SLO hampers the immune
response. Mice that have abnormal SLO microarchitecture due
to deletion of the LT-b receptor gene have severely diminished
cytotoxic T cell (CTL) responses and delayed viral clearance
when infected with ARM (Berger et al., 1999). Disruption of
lymphoid architecture, in which there is loss of architecture,
FRC/follicular DC networks, and/or defined areas for T, B, and
other lymphocytes, has been reported with a variety of patho-
gens, including LCMV, HIV, and SIV (Benedict et al., 2006;
Tishon et al., 1993; Zeng et al., 2012a). During Cl-13 infection,
mice exhibit severe lymphoid disorganization concomitant with
loss of T cell function and immune suppression (Mueller et al.,
2007b; Teijaro et al., 2013; Tishon et al., 1993). Similarly,
lymphoid structure is damaged during HIV and SIV infection as
a result of fibrosis, leading to disrupted T cell homeostasis
(Zeng et al., 2012a) by limiting T cell access to IL-7-expressing
FRCs, thus causing T cell apoptosis and decreased numbers
of naive T cells (Zeng et al., 2012a). The damage is compounded
by the dependency of FRCs on LT-b expressed by CD4 T cells,
resulting in a cyclical loss in both cell populations (Zeng et al.,
2012a; Zeng et al., 2012b). The loss of T cells and FRCs likely im-
pacts T cell recovery, as decreased FRC loss is associated with
better T cell recovery after the initiation of combination antiretro-
viral therapy (cART) (Zeng et al., 2012a). Administration of IL-7
can improve T cell responses in Cl-13, HIV, and SIV (Leone
et al., 2009; Nanjappa et al., 2011), supporting the importance
of cellular sources of IL-7 such as FRCs during infection. Overall,
the role of lymphoid stromal cells as regulators of immune cell
survival, function, and migration indicates that understanding
their function and impact on lymphoid environment, specifically
during viral infections, is necessary to plan strategies to initiate
and maintain behaviors critical to B and T cell responses.
Chronic Inflammation, Immune Activation, and Type I
IFN during Persistent Infection: Bridging Innate and
Adaptive Immunity
Chronic inflammation and immune activation during persistent
infection is associated with multiple immunologic dysfunctions,
including aberrant T cell activation, cell senescence and deple-
tion, dysfunctional B cell responses and polyclonal B cell
Figure 2. Characteristics of Acute Versus
Persistent Viral Infection
Viral infection results in one of two outcomes:
clearance or persistence. Clearance of virus in the
acute phase is characterized by vigorous expan-
sion of virus-specific T cells with anti-viral activity.
Viral persistence is characterized by an initial T cell
expansion similar that of an acute infection.
However, when virus is not cleared in the acute
phase then T cells experience decreasing function
(i.e., T cell exhaustion) that may lead to deletion of
the cell. The T cell exhaustion is partially caused by
the expression of negative immune regulators
such as IL-10 and PD-1. Many viruses that cause
persistent infection also target DCs by suppress-
ing or subverting their function. Together these
factors not only contribute to establishing persis-
tent infection but also hinder the formation of
memory responses.
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lymphoid architecture and in HIV infection, increased morbidity,
and mortality (Appay and Sauce, 2008; Chang and Altfeld,
2010;Moir et al., 2011). Importantly, immuneactivation is strongly
associatedwith andpredictiveofHIVdiseaseprogressioneven in
patients with antiretroviral therapy suppressed viral loads (Moir
et al., 2011; Sauce et al., 2013). Mounting evidence suggests
that IFN-I are integrally associated with immune activation (Bo-
singer et al., 2011; Chang and Altfeld, 2010; Hardy et al., 2013),
suggesting that targeting this pathway could have a tremendous
therapeutic impact to halt and potentially reverse immune deteri-
oration and HIV disease progression. Recently, using LCMV, we
established a direct link between chronic IFN-I signaling, immune
suppression, and viral persistence (Teijaro et al., 2013; Wilson
et al., 2013). Like other persistent infections (Appay and Sauce,
2008; Sauce et al., 2013), Cl-13 infection induced significantly
higher IFN-I levels and IFN-stimulated gene expression than
acute ARM infection (Teijaro et al., 2013; Wilson et al., 2013),
consistent with the association between high levels of IFN-I sig-
naling andpersistence. Short-termsuppression of IFN-I signaling
at the onset of infection corrected multiple dysfunctions associ-
atedwith persistent viral infections, including increased numbers
and stimulatory capacity of APCs, reduced expression of nega-
tive immune regulators such as the anti-inflammatory cytokine
interleukin-10 (IL-10) and inhibitory ligand PD-L1, prevention of
lymphoid tissue disruption, and enhanced numbers and poly-
functionality of virus-specificCD4 T cells (Teijaro et al., 2013;Wil-
son et al., 2013). Interestingly, therapeutic blockade of chronic
IFN-I signaling well into persistent infection diminished IL-10
and PD-L1 expression and substantially decreased virus titers
in multiple organs, indicating the continued potentiation of the
immunosuppressive programby IFN-I signaling and, importantly,
the ability to disrupt IFN-I signaling to treat persistent infection.
Although themechanisms underlying enhanced immune function
through IFN-I blockade are under investigation, control of persis-
tent infection depended on an initial CD4 T cell response and
IFN-g expression (Teijaro et al., 2013;Wilson et al., 2013). In addi-Cell Host & Microbetion to these factors, the myriad of im-
mune alterations that occur when IFN-I
signaling is inhibited are complex, inter-
dependent and likely all combine indistinct ways to culminate in the enhanced control of persistent
LCMV infection. In HIV infection, strategies that indirectly or
directly target IFN-I indicate decreased immune activation and
immunosuppressive factors, suggesting that inhibiting IFN-I in
HIV infection may also have therapeutic benefit (Ries et al.,
2012). As discussed above, IFN-I have important antiviral effects
and are a well-established treatment for HCV and potentially HIV
(Azzoni et al., 2013). Together, these results highlight the duality
and temporal nature of IFN-I during viral infection wherein acute
signals possess antiviral and immune stimulatory potential, but
when infection is not controlled in a timely fashion, prolonged
IFN-I signaling leads to multiple immune dysfunctions that facili-
tate persistent infection. Future exploration into how excessive
IFN-I signaling simultaneously activates and suppresses the
immune response and the overall balance between its antiviral
versus immunoregulatory effect will lead to important insights
into the pathogenesis of persistent virus infections and potential
strategies to treat these infections.
T Cell Responses during Persistent Viral Infections
Control of persistent viral infection depends upon effective anti-
viral CD4+ and CD8+ T cell responses (Oldstone, 2006). CD8
T cells (i.e., CTLs) express inflammatory and antiviral cytokines
and lyse-infected cells. CD4 T cells (i.e., helper T cells) have a
myriad of roles that include expression of inflammatory cyto-
kines, DC licensing, optimal activation, and maintenance of
CTLs and generation of B cell and antibody responses. During
acute LCMV-ARM infection, T cell responses are robust and
CD8 T cells alone are necessary for viral clearance (Tishon
et al., 1995). During Cl-13 infection, the immune environment
and T cell responses are initially comparable to those in acute
ARM infection (Brooks et al., 2006a; Wilson et al., 2012). Howev-
er, within 1–2 weeks after infection, LCMV-specific T cells enter
an attenuated (i.e., exhausted) state, characterized by a hierar-
chical loss of proliferative ability, production of key antiviral
and immune stimulatory cytokines, and cytolytic activity (Brooks
et al., 2005; Wherry, 2011) (Figure 2). This loss of T cell effector13, June 12, 2013 ª2013 Elsevier Inc. 655
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observed in HIV (Wilson and Brooks, 2010). The loss of T cell
functionality during persistent infection is compounded by the
decreased ability of the immune system to mount de novo
immune responses against co-infecting pathogens, thereby
rendering the host less able to fight infection and potentially
form memory T cells (Ahmed et al., 1984; Oldstone et al.,
1988). However, in some instances, the ongoing production of
IFN-I and/or IFN-g during persistent infections has been re-
ported to protect the host from secondary infections (Barton
et al., 2007; Valentine et al., 2012). Thus, proper generation
and maintenance of antiviral activity is paramount to clear the
virus infection, and functional perturbations can have a profound
impact on the outcome of infection.
CD8 T Cell Responses during Persistent Viral Infection
Disrupting the generation of CTLs results in delayed and/or failed
virus clearance, and abrogation of CTL function contributes to
the inability to control multiple persistent infections (Wherry,
2011). Themaintenance of CD8 T cell function during exhaustion
as well as the targeting of conserved epitopes necessary for viral
function correlates with stronger viral control (Ladell et al., 2013;
Mendoza et al., 2013; Vingert et al., 2012). Extensive transcrip-
tional and epigenetic profiling of CD8 T cells of functionally active
CTLs versus ‘‘exhausted’’ CTLs revealed differences in a variety
of genes for inhibitory receptors, transcription factors, metabolic
pathways, chemotaxins, and migration factors (Doering et al.,
2012; Wherry, 2011; Wherry et al., 2007; Youngblood et al.,
2012). A key class of factors is that of negative immune regula-
tors, which have been summarized in a recent review (Wherry,
2011). Consequently, we will primarily discuss negative regula-
tors that have been shown by either in vivo gene deletion or
antibody neutralization studies to play a major role in viral persis-
tence, programmed death-1 (PD-1), and IL-10. These molecules
are upregulated during inflammatory responses to control the
immune response and prevent host damage. However, during
persistent infections characterized by high viral replication, these
molecules, although crucial for limiting immunopathology, also
suppress T cell responses, resulting in uncontrolled viral load.
PD-1, a member of the CD28 receptor family, negatively regu-
lates T cell signaling by binding its cognate ligands PD-L1 and
PD-L2 (Sharpe et al., 2007). High levels of PD-1 are expressed
on exhausted CD4+ and CD8+ T cells during persistent LCMV
infection and blockade of PD-1 signaling via PD-L1 leads to
accelerated Cl-13 clearance (Barber et al., 2006). PD-L1 is ex-
pressed on many cell types during viral persistence, including
hematopoietic and nonhematopoietic cells with the type of cell
presenting PD-L1 having a distinct impact on CD8 T cell re-
sponses (Mueller et al., 2010). Multiple APCs express PD-L1
during persistent infection and upon interaction with T cells
induce and sustain T cell exhaustion (Barber et al., 2006; Wilson
et al., 2012). In conjunction, stromal FRCs also negatively
regulate activated antiviral T cells via expression of PD-L1 to pre-
vent immunopathology (Mueller et al., 2007b; Mueller et al.,
2010; Ng et al., 2012) but, consequently, clearance of infected
cells is slowed. Although PD-L1 expression on hematopoietic
versus nonhematopoietic cells play slightly different roles, both
contribute to suppressing T cell activity and compromise control
of infection.656 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.The discovery of PD-1 as a marker of T cell exhaustion in the
LCMV system quickly led to examination of PD-1 in HIV, HCV,
andHBV infectionswhere PD-1 is also upregulated on virus-spe-
cific CD8 T cells and correlates with T cell exhaustion (Yi et al.,
2010b). For HIV, in vitro PD-L1 blockade resulted in augmented
expansion and cytokine production by HIV-specific T cells (Day
et al., 2006; Petrovas et al., 2006) and studies using humanized
mice demonstrated enhanced T cell responses and decreased
HIV titers following PD-1 blockade (Palmer et al., 2013). Further,
PD-L1 blockade in SIV-infected macaques demonstrated
improvements in SIV-specific CD8 T cell and B cell function
(Hofmeyer et al., 2011). Similarly, in vitro blockade of PD-L1
improved proliferation and function of HCV-specific CD8
T cells (Fisicaro et al., 2010; Urbani et al., 2008). However, the
efficacy of PD-L1 blockade may depend on PD-1 expression
level, which correlates with the extent of T cell exhaustion, as
HCV-specific CD8 T cells from chronic HCV patients with high
PD-1 expression were less responsive than those with interme-
diate PD-1 expression to PD-L1 blockade (Blackburn et al.,
2008; Nakamoto et al., 2008). The research on the PD-1:PD-L1
pathway is a work in progress but represents a promising target
for improving/restoring the function of exhausted T cells.
In combination with PD-1, T cell immunoglobulin and mucin
domain-containing molecule-3 (TIM-3) and lymphocyte activa-
tion gene (LAG-3), two other negative immune regulators, may
be promising targets to treat T cell exhaustion (Wherry, 2011).
During LCMV infection, a majority of virus-specific CD8+
T cells coexpress Tim-3 and PD-1, which is associated with
increased CD8 T cell exhaustion when compared to expression
of either factor alone (Jin et al., 2010; Jones et al., 2008).
Blockade of TIM-3 enhanced the ex vivo function of exhausted
CD8 T cells from HIV infection (Jones et al., 2008), and during
persistent LCMV infection, simultaneous blockade in vivo of
both TIM-3 and PD-1 synergistically improved CD8+ T cell re-
sponses and viral control (Jin et al., 2010). LAG-3 blockade or
deletion alone does not improve T cell responses or viral control
(Richter et al., 2010) but simultaneous blockade of PD-1 and
LAG-3 results in synergistic alleviation of T cell exhaustion and
viral control (Blackburn et al., 2009), suggesting that LAG-3,
along with TIM-3, are sub-dominant suppressive pathways.
Thus, the combinatorial regulation of T cell exhaustion by inhib-
itory receptors is complex, but suggests that it may be possible
to specifically interfere with precise signaling pathways to
restore desired responses while still maintaining regulation to
prevent excessive immunopathology.
T cell expression of these inhibitory receptors is controlled by
the transcriptional repressor Blimp-1, a regulator of cell differen-
tiation (Shin et al., 2009), and transcription factors T-bet and
eomesodermin (Eomes) that direct T cell fate (Castellino andGer-
main, 2006a; Pearce et al., 2003). Both Blimp-1 and Eomes are
highly expressed in exhausted CD8 T cells in association with
PD-1 and other inhibitory receptors (Paley et al., 2012; Shin
et al., 2009; Wherry et al., 2007). Conversely, T-bet is reduced
in virus-specific CD8+ T cells during chronic HIV and LCMV,
and this reduction correlates with T cell dysfunction (Hersperger
et al., 2011; Kao et al., 2011). Recently, Paley and colleagues
identified a progenitor or ‘‘stem’’-like exhausted CD8 T cell
that expressed T-bet and was capable of differentiating into
Eomes-expressing subset with enhanced virus fighting capacity
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strategies to enhance CD8 T cell responses during persistent
infection should additionally focus on amplifying specific subsets
of CD8 T cells. How best tomodulate transcriptional programs to
achieve a desired response and how this affects control of virus
replication will be an interesting line of future research.
IL-10 is another key negative immune regulator that is impor-
tant duringmultiple persistent virus infections. IL-10 exerts pleio-
tropic effects on different cell populations and likely with diverse
suppressive roles during persistent infection (Ouyang et al.,
2011; Wilson and Brooks, 2011). During persistent LCMV-Cl13
infection, IL-10 is significantly upregulated and results in a
decrease in virus-specific T cells and a loss of T cell functionality
(Brooks et al., 2006b; Ejrnaes et al., 2006). Deletion of the il10
gene or early blockade of the IL-10 receptor (IL-10R) is sufficient
to prevent both events (Brooks et al., 2006b; Ejrnaes et al., 2006).
Although IL-10 can be expressed by multiple cell types, one of
the main producers of IL-10 during Cl-13 infection is CD8a
CD11b+ DCs (Ng and Oldstone, 2012; Wilson et al., 2012).
Comparatively, IL-10 is only minimally expressed by DCs in
ARM-infected mice (Brooks et al., 2006b; Wilson et al., 2012).
Interestingly, distinct APC subsets that produce IL-10 also ex-
pressed high levels of the other suppressive factors that limit
antiviral immunity during persistent infection (e.g., PD-L1, indole-
amine 2,3 dioxygenase [IDO]) (Ng and Oldstone, 2012; Wilson
et al., 2012), suggesting a potential mechanismwhereby expres-
sion of multiple immunoregulatory factors on single cells facili-
tates the simultaneous delivery of numerous inhibitory signals
directly to individual T cells in a single interaction. In addition to
initiating the suppressive state, IL-10 is also necessary to main-
tain T cell exhaustion (Brooks et al., 2008b). Antibody blockade
of IL-10 signaling during persistent infection restored the func-
tion of exhausted T cells and significantly decreased viral titers
(Brooks et al., 2006b, 2008b). Interestingly, PD-L1 and IL-10
signal via independent pathways yet blockade of either pathway
alone restores T cell function (Brooks et al., 2008a). Examination
of IL-10 in human persistent infections has identified increased
levels in HIV (Landay et al., 1996; Navikas et al., 1995), HBV
(Peppa et al., 2010), and HCV (Crawford et al., 2011) infection,
and IL-10 production has been described in DCs, monocytes,
natural killer (NK) cells, and nonregulatory T cells (Alter et al.,
2010; Brockman et al., 2009; Torheim et al., 2009). Furthermore,
IL-10 has been implicated in the lysis of mature DCs by NK cells
(Alter et al., 2010) as well as regulation of CD4 T cell death (Clerici
et al., 1994; Estaquier et al., 1995) during HIV infection. Although
in vivo studies have yet to be performed to assess the efficacy of
anti-IL-10 treatment in human chronic viral infections, in vitro
blockade of IL-10 leads to improved function of exhausted
T cells during HIV infection (Brockman et al., 2009; Landay
et al., 1996) and HCV (Kaplan et al., 2008; Rigopoulou et al.,
2005). Although data thus far indicates that IL-10 is a key sup-
pressive pathway in persistent infection, further investigation of
anti-IL-10 treatment will determine if this is a viable strategy to
decrease T cell exhaustion in human chronic infections.
CD4 T Cell Differentiation during Persistent Virus
Infection
CD4 T cells have multiple roles and are essential to support CD8
T cell responses (Battegay et al., 1994; Matloubian et al., 1994).The scope of CD4 T cell help during viral infection is complex, but
essential helper functions within persistent viral infection include
(1) sustaining residual function in exhausted CD8 T cells, (2)
providing help to B cells to elicit antiviral antibody responses,
and (3) licensing of new APCs to sustain antiviral immunity or
invoke new antiviral responses (Figure 3) (Fahey and Brooks,
2010b). In response to the levels/combination of antigen stimu-
lation, costimulatory signals, and cytokines encountered, CD4
T cells develop into different Th subsets that preferentially stim-
ulate and sustain CD8 T cells (Th1) and B cells (T follicular helper;
Tfh), suppress T cell activity (Treg), or secrete other key immune
driving cytokines (Th17, Th2) (Crotty, 2011; Zhu et al., 2010). Due
to their ability to differentially direct and sustain specific immune
responses, the type of CD4 T cell response elicited is critical to
guiding the ensuing response and controlling infection. While
the majority of studies have focused on understanding CD8
T cell dynamics in persistent infection, CD4 T cell responses
are an essential correlate of control and/or clearance of multiple
persistent virus infections, including HIV and HCV (Day et al.,
2003; Gerlach et al., 1999; Grakoui et al., 2003; Rosenberg
et al., 1997; Thimme et al., 2001). Thus, identifying the mecha-
nisms through which CD4 T cells modulate and sustain immunity
to control persistent infection is highly important and will poten-
tially provide strategies to simultaneously correct multiple
immune cell types and functions that are lost during persistent
infection.
Upon Cl-13 infection, CD4 T cells progressively lose the ability
to produce key antiviral Th1 cytokines (Fahey et al., 2011). How-
ever, CD4 T cells are required to control and eventually resolve
persistent infection, indicating that they must retain some helper
function to sustain immunity. Indeed, viral persistence results in
an alteration or redirection of CD4 T cell responses wherein Th1
cells are progressively transformed into Tfh cells (Brooks et al.,
2005; Fahey et al., 2011). The accumulation of Tfh cells was
also recently identified in persistent SIV and HIV infection and
correlated with increased B cell activation and antibody produc-
tion (Lindqvist et al., 2012; Petrovas et al., 2012). While this pro-
gressive development into B cell helping Tfh cells is critical to
sustain the humoral arm of the antiviral response and control
infection (Fahey et al., 2011; Harker et al., 2011), the dwindling
number of Th1 cells may quantitatively impact CD8 T cell main-
tenance contributing to the observed CTL exhaustion. Although
potentially sacrificing an important branch of antiviral immunity,
the skew away from Th1 cells may be a protective mechanism
to limit immunopathology in the face of high levels of infected
cells during persistent infection.
CD4 T Cell Help for CD8 T Cell Responses
CD4 T cells are required throughout viral persistence to sustain
CD8 T cell function and control infection, to avert deletion of
high-affinity antiviral CTL, and to purge an established persistent
viral infection (Battegay et al., 1994; Berger et al., 2000; Castel-
lino and Germain, 2006b; Matloubian et al., 1994). Resolution of
HCV infection and resistance to re-infection correlates with
strong virus-specific CD4 T cell responses that sustain antiviral
CD8 T cell activity (Day et al., 2003; Grakoui et al., 2003; Thimme
et al., 2001; Urbani et al., 2006). Subsequent loss of CD4 T cell
activity after initial control of HCV or LCMV allows the virus to
re-emerge and the loss of CD4 T cells is a pivotal mechanismCell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc. 657
Figure 3. Helper functions of CD4 T cells during persistent virus infection
Although the functional outcomes of CD4 T cell help to CD8 T cells and B cells are well documented in persistent viral infection, the precise mechanisms of help
remain largely an unknown black box. CD4 T cells can help CD8 T cells andB cells through the secretion of cytokines, such as IL-21, IL-2 and likely others awaiting
discovery. Furthermore, it is also probable that CD4 T cells can secondarily help antiviral CD8 T cells by continually licensing new dendritic cells, perhaps through
CD40/CD40L signaling, cytokines and/or other costimulatory pathways. CD4 T follicular cells are necessary for antiviral antibody production. Cytotoxic CD4
T cells have also been identified in many persistent viral infections and potentially ‘‘help’’ by directly lysing virally infected APCs, such as macrophages in HIV
infection.
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2001; Schulze Zur Wiesch et al., 2012). Defective CD8 T cell pro-
liferative responses against HIV were augmented in vivo by
induction of CD4 T cells in patients with suppressed virus
loads (Lichterfeld et al., 2004), demonstrating the desirability of
invoking CD4 T cells to control an established persistent infec-
tion. Effective CD4 T cell responses are critical to sustain antiviral
CD8 T cells to control persistent virus infection and loss of their
activity is a critical step in disease progression.
Although the importance of CD4 T cell help to CD8 T cells is
well established, the precise mechanisms by which CD4
T cells mediate their helper functions have remained elusive
(Figure 3). Recently, a direct role for IL-21 (a common g-chain
cytokine familymember) inmaintaining CD8 T cell functionwithin
persistent LCMV infection was identified (Elsaesser et al., 2009;
Fro¨hlich et al., 2009; Yi et al., 2009). Unlike other cytokines, IL-21
expression is enhanced and sustained during prolonged viral
replication (Elsaesser et al., 2009; Fro¨hlich et al., 2009; Yi et al.,
2009). IL-21 signaling maintained both the number of virus-spe-
cific CD8 T cells and their ability to produce antiviral cytokines.
Interestingly, despite antigen-specific CD4 T cell numbers being
unchanged or even elevated in IL-21R/ mice, these mice
were unable to sustain CD8 T cell responses or control infection
(Elsaesser et al., 2009), demonstrating the specific role of IL-
21-mediated help. Similarly, enhanced IL-21 expression was658 Cell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc.observed in HIV-infected patients and its levels correlated with
relative control of infection (Chevalier et al., 2011; Yue et al.,
2010). Ex vivo culture of HIV-specific CD8 T cells with IL-21 led
to their expansion and aided their ability to inhibit viral replication
in vitro (Chevalier et al., 2011; Yue et al., 2010). In addition to IL-
21, loss of signaling by IL-2, a cytokine that largely acts on lym-
phocytes, also diminished LCMV-specific CD8 T cell responses
in vivo (Bachmann et al., 2007) and correlated with loss of HIV-
specific CD8 T cells (Lichterfeld et al., 2004). The source of
IL-2 is likely CD4 T cells but may also be derived from other
cell types, particularly since CD4 T cell-derived IL-2 is greatly
diminished in persistent infection (Brooks et al., 2005; Lichterfeld
et al., 2004). However, it is clear that multiple cytokines function
in combination to sustain CD8 T cells during long-term virus
replication and that loss of one cytokine dramatically impacts
the maintenance of antiviral CD8 T cells. Ultimately, it will be
important to determine the compilation of factors that sustain
antiviral CD8 T cells, how they individually contribute to distinct
CD8 T cell effector functions, and how these effector functions
lead to prevention and control of persistent infection.
T Follicular Helper Cells and B Cell Responses
In addition to CD8 T cells, B cell and antibody responses are
required to control persistent infection, and specifically, persis-
tent infections associated with multiple B cell dysfunctions
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subset of CD4 T cells essential for providing B cell help. Changes
in the dynamics of the Tfh population could lead to many of the
observed alterations in B cell activation (Crotty, 2011; Moir and
Fauci, 2009). Tfh cells interact with B cells in follicles and
germinal centers where B cells mature and differentiate to
provide proliferative and survival signals and facilitate affinity
maturation and class switch recombination, which improves
the function of antibodies produced by B cells (Crotty, 2011).
CD4 T cells maintain their B cell helper function throughout
persistent viral infection; although, due to intrinsic and extrinsic
mechanisms, the help they provide may be attenuated (Cubas
et al., 2013; Fahey et al., 2011). Depletion of CD4 T cells
after infection or preventing Tfh:B cell interactions abrogated
LCMV-specific antibody production and importantly the ability
to clear infection (Fahey et al., 2011; Harker et al., 2011),
indicating that the continual presence of Tfh and interaction
with B cells is required to sustain humoral immunity through viral
persistence.
Many persistent viral infections exhibit delayed production of
virus-specific neutralizing antibodies and are characterized as
having elevated levels of nonspecific antibody production
(Hangartner et al., 2006; Moir and Fauci, 2009). The elevation
in nonspecific antibodies correlates with viral load, is CD4
T cell dependent, and may arise from the presentation of viral
peptides by viral nonspecific B cells (Hunziker et al., 2003). The
enhancement of Tfh cells in viral persistence most likely fuels
this nonspecific B cell activation. Indeed, by reducing CD4
T cell numbers in vivo, nonspecific antibody levels were
decreased while increased neutralizing antibody titers arose
earlier in infection (Recher et al., 2004). These data suggest
that in some cases the skew toward Tfh could be detrimental,
facilitating nonspecific antibody activation and augmenting the
risk of autoimmune disease.
In addition to effects on CD8 T cells, it is highly probable that
IL-21 also influences B cell responses in persistent infection. IL-
21 is highly expressed by Tfh (Crotty, 2011; Fahey et al., 2011)
and known to promote germinal center B cell formation and
the differentiation of plasma cells, which are B cells that produce
high levels of antibodies, thus leading to antibody production (Yi
et al., 2010a). IL-21/ and IL-21R/ mice had a 2- to 3-fold
defect in antibody production during persistent LCMV infection
(Elsaesser et al., 2009; Fro¨hlich et al., 2009; Yi et al., 2009), likely
due to a direct effect on B cells. Interestingly, although IL-21 is
highly expressed by Tfh, it should be noted that upon persistent
LCMV infection IL-21 can be produced by both Tfh and non-Tfh
CD4 T cells (Fahey et al., 2011), likely accounting for its ability to
help both CD8 T cells and B cells, as discussed above. Further
research is required to delineate the molecular mechanisms
through which IL-21 mediates its effects on B cells and CD8
T cells.
The role of B cells in the control of persistent virus infection is
well established (Moir and Fauci, 2009). Yet, the cellular immu-
nology of B cell responses during persistent virus infections is
less well characterized in part owing to the difficulty in studying
them. Extensive B cell dysfunction is observed during HIV infec-
tion (Moir and Fauci, 2009), and during persistent LCMV infec-
tion, the highest affinity antibody bearing B cells are physically
deleted, likely leading to defects in the B cell repertoire and gen-eration of neutralizing antibodies (Hangartner et al., 2006). One
result of B cell dysfunctionmay be alterations in antibody isotype
production and/or glycosylation that could differentially affect Fc
receptor binding/usage leading to decreased antibody depen-
dent cellular cytotoxicity (ADCC) by NK cells and antibody-
dependent cellular phagocytosis (ADCP), both of which have
an important impact on clearing virus-infected cells and free
virions (Ackerman et al., 2013a; Ackerman et al., 2013b). Further,
B cell dysfunction in HIV may hinder the development of broadly
neutralizing antibodies, which require extensive rounds of affinity
maturation to achieve broad neutralization (Klein et al., 2013);
this is likely compounded by lymphoid disruption (Zeng et al.,
2012a) and the loss of CD4 T cell help (Crotty, 2011). Because
of the potential of antibody to neutralize virus and hence prevent
persistent infection, passive and genetic-based antibody immu-
notherapies have great appeal (Burton et al., 2012; Law et al.,
2008). The recent technologic advances in glycomics and iden-
tification of antigen-specific B cells will undoubtedly lead to
important insights into B cell dysfunctions, how they contribute
to the inability to generate neutralizing antibodies and clear
infection, and, ultimately, how to modulate the B cell response
to generate protective and therapeutic antibodies to control
persistent infection.
Cytotoxic CD4 T cells
In addition to helping CD8 T cells and B cells to resolve infection,
CD4 T cells also have direct cytotoxic function in multiple viral
infections (Marshall and Swain, 2011), including persistent infec-
tions such as HIV (Norris et al., 2004; Zaunders et al., 2004), HBV,
and HCV (Aslan et al., 2006). Much like the mechanisms used by
CTLs, CD4 T cells kill target cells via multiple mechanisms,
including the release of perforin and granzyme, which act in
concert to create pores in the target cell that induce cell death,
and by FasL engagement of Fas on the cell surface to induce
apoptosis (Marshall and Swain, 2011). Cytotoxic CD4 T cells
have MHC class II restricted killing (Jellison et al., 2005), and
therefore most likely target APCs. In addition, human CD4
T cells also upregulate MHC class II upon activation (Holling
et al., 2002), raising the question of whether they are targets
in vivo (Streeck et al., 2013). A recent report identified early
CD4 CTL activity as a predictor of enhanced long-term HIV con-
trol (Soghoian et al., 2012), suggesting that the ability to generate
these CD4 killer cells could prove therapeutically valuable to
control persistent virus infections. Although the dissection of
the nature of CD4 T cell help in persistent infection remains
experimentally challenging, understanding these mechanisms
will be invaluable, and once elucidated will allow for derivation
of strategies to enhance these functions.
Conclusion
The current understanding of how innate and adaptive immune
interactions contribute to persistent viral infection (Table 1) sug-
gests multiple points for potential therapeutic intervention.
Currently, ongoing treatment of persistent viral infections is
limited to drug targeting. Although in some cases these therapies
are able to eliminate HCV, in most instances and particularly for
HIV, they are not a cure and have the problem of long-term ther-
apy, cost, and danger of drug resistance. Thus, a combination of
antiviral drug therapy along with therapies to restore immuneCell Host & Microbe 13, June 12, 2013 ª2013 Elsevier Inc. 659
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CD8 T cells in controlling persistent viral infections and their
ability to sustain the cellular and humoral immune responses
make them attractive targets of current therapeutic research.
Recent evidence for such a possibility is derived from the SIV
system in which CMV vectors encoding SIV epitopes are being
used to invoke and sustain antiviral CD8 T cells that in many
instances effectively control the infection without adjunctive
antiretroviral drug therapy (Hansen et al., 2011). Specific induc-
tion of CD4 T cells may also be an ideal approach as induction or
delivery of virus-specific CD4 T cells can result in enhanced
virus-specific CD8 T cells (Aubert et al., 2011; Lichterfeld et al.,
2004). Another strategy would be to develop small molecule re-
agents to inhibit the negative regulatory pathways that maintain
T cell exhaustion during persistent infection. As important
players in the battle against viral persistence, illumination of
methods to maintain CD4 and CD8 T cell function will be critical
to devising new vaccine and therapeutic strategies. However,
considering the interreliance of the immune system, it is likely
that effective preventative or restorative therapies will require
enhancement of multiple immune subsets (e.g., antiviral CD8
T cells to kill cells, B cell to produce antibody to neutralize free
virus, and CD4 T cells to sustain both of their activity). Such an
integrated approach requires in-depth understanding about
how persistent infections are established, maintained, and elim-
inated from an immunological standpoint.
To further our understanding of immunological events during
persistent infections, research is needed to illuminate several
key areas. First, studies are needed to determine whether DC/
APC functions can be fostered to boost generation of new
immune responses in the presence of immune suppressive pro-
gramming during persistent infection. Second, it is necessary to
better identify how lymphocyte trafficking and interactions
change during chronic viral infections and the effect on the gen-
eration andmaintenance of antiviral responses. Identifying these
interactions and how to influence them will be an important leap
forward in understanding how to prevent or ‘‘fix’’ the abnormal
immune responses generated during chronic infections. Third,
we need a better understanding of CD4 T cell regulation and dif-
ferentiation during viral infection and the effects on sustaining
and directing both antiviral CD8 and B cell responses. Specif-
ically, studies are needed to further elucidate precise mecha-
nisms and factors that comprise CD4 T cell help during
persistent infection, the optimal Th response to elicit, and the
distinct Th cell fate decisions that lead to increased or decreased
control of persistent virus replication. Lastly, examination of how
IFN-I controls the multiple immune parameters and how those
events control CD4 T cell responses will lend better insight into
causes and control of viral persistence. By identifying these
immune interactions and learning how to influence them, the field
of immunologywill take an important leap forward in understand-
ing how to prevent or overcome immune exhaustion and opti-
mally tailor immune response to eliminate persistent infections.ACKNOWLEDGMENTS
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